TY - JOUR
T1 - Screening for Obstructive Sleep Apnea in Adults
T2 - US Preventive Services Task Force Recommendation Statement
AU - Mangione, Carol M.
AU - Barry, Michael J.
AU - Nicholson, Wanda K.
AU - Cabana, Michael
AU - Chelmow, David
AU - Rucker Coker, Tumaini
AU - Davidson, Karina W.
AU - Davis, Esa M.
AU - Donahue, Katrina E.
AU - Jaén, Carlos Roberto
AU - Kubik, Martha
AU - Li, Li
AU - Ogedegbe, Gbenga
AU - Pbert, Lori
AU - Ruiz, John M.
AU - Stevermer, James
AU - Wong, John B.
N1 - Publisher Copyright:
© 2022 American Medical Association. All rights reserved.
PY - 2022/11/15
Y1 - 2022/11/15
N2 - Importance: Current prevalence of obstructive sleep apnea (OSA) in the US is not well established; however, based on cohort and survey data, in 2007-2010 the estimated prevalence of at least mild OSA (defined as an apnea-hypoxia index [AHI] ≥5) plus symptoms of daytime sleepiness among adults aged 30 to 70 years was 14% for men and 5% for women, and the estimated prevalence of moderate to severe OSA (defined as AHI ≥15) was 13% for men and 6% for women. Severe OSA is associated with increased all-cause mortality. Other adverse health outcomes associated with untreated OSA include cardiovascular disease and cerebrovascular events, type 2 diabetes, cognitive impairment, decreased quality of life, and motor vehicle crashes. Objective: To update its 2017 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for OSA in adults. Population: Asymptomatic adults (18 years or older) and adults with unrecognized symptoms of OSA. Evidence Assessment: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for OSA in the general adult population. Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for OSA in the general adult population. (I statement).
AB - Importance: Current prevalence of obstructive sleep apnea (OSA) in the US is not well established; however, based on cohort and survey data, in 2007-2010 the estimated prevalence of at least mild OSA (defined as an apnea-hypoxia index [AHI] ≥5) plus symptoms of daytime sleepiness among adults aged 30 to 70 years was 14% for men and 5% for women, and the estimated prevalence of moderate to severe OSA (defined as AHI ≥15) was 13% for men and 6% for women. Severe OSA is associated with increased all-cause mortality. Other adverse health outcomes associated with untreated OSA include cardiovascular disease and cerebrovascular events, type 2 diabetes, cognitive impairment, decreased quality of life, and motor vehicle crashes. Objective: To update its 2017 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for OSA in adults. Population: Asymptomatic adults (18 years or older) and adults with unrecognized symptoms of OSA. Evidence Assessment: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for OSA in the general adult population. Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for OSA in the general adult population. (I statement).
UR - http://www.scopus.com/inward/record.url?scp=85142400774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142400774&partnerID=8YFLogxK
U2 - 10.1001/jama.2022.20304
DO - 10.1001/jama.2022.20304
M3 - Review article
C2 - 36378202
AN - SCOPUS:85142400774
SN - 0098-7484
VL - 328
SP - 1945
EP - 1950
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 19
ER -